784 related articles for article (PubMed ID: 17986302)
1. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
Flytström I; Stenberg B; Svensson A; Bergbrant IM
Br J Dermatol; 2008 Jan; 158(1):116-21. PubMed ID: 17986302
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life.
Ho SG; Yeung CK; Chan HH
Clin Exp Dermatol; 2010 Oct; 35(7):717-22. PubMed ID: 19925489
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
Salim A; Tan E; Ilchyshyn A; Berth-Jones J
Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate and ciclosporin combination for the treatment of severe psoriasis.
Aydin F; Canturk T; Senturk N; Turanli AY
Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
7. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
Fraser AD; van Kuijk AW; Westhovens R; Karim Z; Wakefield R; Gerards AH; Landewé R; Steinfeld SD; Emery P; Dijkmans BA; Veale DJ
Ann Rheum Dis; 2005 Jun; 64(6):859-64. PubMed ID: 15528283
[TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
10. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
[TBL] [Abstract][Full Text] [Related]
11. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting.
de Korte J; van der Valk PG; Sprangers MA; Damstra RJ; Kunkeler AC; Lijnen RL; Oranje AP; de Rie MA; de Waard-van der Spek FB; Hol CW; van de Kerkhof PC
Br J Dermatol; 2008 Feb; 158(2):375-81. PubMed ID: 18067483
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
13. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
Zachariae C; Mørk NJ; Reunala T; Lorentzen H; Falk E; Karvonen SL; Johannesson A; Claréus B; Skov L; Mørk G; Walker S; Qvitzau S
Acta Derm Venereol; 2008; 88(5):495-501. PubMed ID: 18779890
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial.
Lajevardi V; Hallaji Z; Daklan S; Abedini R; Goodarzi A; Abdolreza M
Int J Dermatol; 2015 Jan; 54(1):95-101. PubMed ID: 25209868
[TBL] [Abstract][Full Text] [Related]
15. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
17. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
18. The use of ciclosporin in psoriasis: a clinical review.
Ho VC
Br J Dermatol; 2004 May; 150 Suppl 67():1-10. PubMed ID: 15115440
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis--a randomized single-blinded placebo-controlled study.
Mahajan R; Kaur I; Kanwar AJ
J Eur Acad Dermatol Venereol; 2010 May; 24(5):595-600. PubMed ID: 20015056
[TBL] [Abstract][Full Text] [Related]
20. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]